This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cerulean Pharma To Present Data On CRLX101's HIF-1a Inhibition At The American Association For Cancer Research Annual Meeting

CAMBRIDGE, Mass., April 4, 2013 /PRNewswire/ --  Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that researchers will present both pre-clinical and clinical data on Cerulean's Phase 2 candidate, CRLX101, in sessions at the American Association for Cancer Research (AACR) Annual Meeting. Among the findings, Cerulean will share clinical data from a study evaluating synergy between CRLX101 and Avastin® (bevacizumab).

(Logo: )

In multiple animal models, CRLX101 inhibits hypoxia-inducible factor 1a (HIF-1a), which is involved in cancer survival mechanisms, and which is up-regulated in the hypoxic conditions created by anti-angiogenic drugs. Animal models suggest that CRLX101 is synergistic with multiple anti-angiogenic drugs, and this hypothesis is being tested in a clinical trial combining CRLX101 with Avastin, the leading anti-angiogenic medicine.

Dr. Stephen M. Keefe, the Ann B. Young Assistant Professor in Cancer Research at the Perelman School of Medicine at the University of Pennsylvania, will present a poster entitled A Phase Ib-2a Study Evaluating the Nanopharmaceutical CRLX101 in Combination with Bevacizumab ( April 9, 8:00 am12:00 pm) on a clinical trial studying synergy between CRLX101 and Avastin when combined to treat patients with advanced renal cell carcinoma. Dr. Keefe, who practices at the Abramson Cancer Center of the University of Pennsylvania, will present data showing that the CRLX101-Avastin combination has been well tolerated in six patients treated to date with no dose limiting toxicities observed. Additional patients are being enrolled in the study to confirm combinability and to assess efficacy.

"The pre-clinical data for CRLX101 in combination with anti-angiogenic agents are very impressive. I am excited that we can bring this combination hypothesis into the clinic, and I am encouraged by the results of this trial to date," said Dr. Keefe. "CRLX101's favorable safety profile is encouraging, and its ability to provide durable inhibition of HIF-1a could increase the benefit that anti-angiogenic agents provide to patients."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,045.81 -4.94 -0.03%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,823.7820 +12.9940 0.27%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs